FDA clears Lilly's Jaypirca as first-line CLL option
The FDA on Oct. 2 approved pirtobrutinib, sold as Jaypirca, for previously untreated CLL or SLL without a 17p deletion. The Lilly drug is the first non-covalent BTK inhibitor cleared for that first-line group. The usual dose is 200 mg once a day.
Adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma gained a new first-line option. On Oct. 2, the Food and Drug Administration approved pirtobrutinib, sold by Eli Lilly as Jaypirca, for patients with no known 17p deletion, the agency and company said.
The drug is a non-covalent Bruton tyrosine kinase inhibitor. It was already used after other BTK drugs failed. The new label lets doctors start it earlier in carefully selected patients. The recommended dose is 200 mg by mouth once a day until the disease grows or side effects become too severe.
Approval rested on the BRUIN CLL-313 trial of 282 patients. An independent review found longer progression-free survival on pirtobrutinib than on bendamustine plus rituximab, a standard chemoimmunotherapy pair. Median progression-free survival was not yet estimable on the Jaypirca arm and was about 33.5 months on the control arm, the FDA said.
CLL is a common slow-growing blood cancer in older adults. The 17p deletion is a genetic change that often makes the disease harder to treat, which is why that group is carved out of this first-line indication.
Patients should ask their oncologist whether genetic testing shows a 17p deletion and how Jaypirca compares with other first-line BTK drugs or antibody combinations. Coverage, prior authorization, and monitoring for infections or bleeding still shape real-world access.
Support groups for CLL patients often share checklists for lab schedules and infection precautions while on BTK drugs. Bring those questions to the first visit after the label change rather than relying on social-media dosing advice.
What we know: FDA approved first-line Jaypirca on Oct. 2 for untreated CLL/SLL without known 17p deletion.
What we don't: How quickly insurers will cover the expanded use and how overall survival will look with longer follow-up.
Where outlets agree The FDA and Eli Lilly both state that pirtobrutinib (Jaypirca) was approved Oct. 2 for previously untreated CLL/SLL with no known 17p deletion at 200 mg daily.
Where they differ Lilly casts the move as a major first-line advance, while some clinicians will wait for longer survival data and payer rules before changing preferred regimens.